Repository logo
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Yкраї́нська
  • Sign In
    New user? Click here to register.Have you forgotten your password?
Repository logo
  • Institutions & Repositories
  • Query NERD by:
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Yкраї́нська
  • Sign In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Akinwumiju CO"

Now showing 1 - 1 of 1
Results Per Page
Sort Options
  • Loading...
    Thumbnail Image
    Item
    Therapeutic effects of aqueous extract of bioactive active component of Ageratum conyzoides on the ovarian-uterine and hypophysis-gonadal axis in rat with polycystic ovary syndrome: Histomorphometric evaluation and biochemical assessment
    (2022) Adelakun SA; Ukwenya VO; Peter AB; Siyanbade AJ; Akinwumiju CO
    Background Polycystic ovary syndrome (PCOS) is an endocrine disorder, affecting women of reproductive age. Ageratum conyzoïdes (AGC) is used traditionally in the treatment of fever, rheumatism, and ulcer. This study investigates the effects of AGC on ovarian-uterine in PCOS rats. Methods Female rats were randomized into four groups (n = 6). Group A control received 2 ml distilled water. Group B received a single dose of 4 mg/kg body weight (bwt) i.p estradiol valerate (EV). Group C received 500 mg/kg bwt AGC and group D received a single dose of 4 mg/kg bwt i.p EV followed by 500 mg/kg bwt AGC orally for 30 days. Parameters tested include follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), estradiol (E2), progesterone (P), C-reactive protein (CRP), interleukin (IL)-6, IL-18 and tumor necrosis factor (TNF)- α, malondialdehyde (MDA), superoxide dismutase (SOD), Catalase (CAT), total protein (TP), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), and ovary and uterus histomorphometric. Results Ageratum conyzoides decrease insulin resistance, obesity indices, TC, TG, LDL, MDA, T, LH, FSH, CRP, IL-6, IL-18, and TNF- α in PCOS rats. And increase HDL, E2, P, TP, CAT, and SOD in PCOS rats. AGC improved ovary and uterus histo-architecture, tertiary, and Graafian follicles, corpus luteum and endometrial thickness increased,and cystic and atretic follicles decreased. Conclusion Ageratum conyzoides improved insulin sensitivity, antioxidant activities, hormonal imbalance, inflammatory makers, and histological changes in PCOS rats. Therefore AGC can be used as a potential adjuvant agent in the treatment of PCOS.
THE NERD SYSTEM

Nigeria Education Repository and Databank (NERD) is the official unified digital platform and a one-stop-shop for the national management, administration, and preservation of education data, records, documents and audio-visual assets as a national reference point for education data consistency - supporting the education sector and library services.

QUICK MENU
  • About NERD
  • Contact and Support
  • Other NERD Services
  • Internal/External Examiner Sign up
  • Student/Lecturer's Sign up
  • Regulatory Agencies
ONGOING ACTION
  • Register Your Institution
  • Training
  • Donate Manuscript
  • Donate Parents' Works
  • Investors
  • Annual Prize and Award
  • Thesis & Dissertation
  • Annual Competition
  • Lecturers' Scholarly Article Prizes
  • Essay Prizes
DIGITAL BANK TOOLS
  • Plagiarism Check
  • NCMVS
  • Publish on NERD
  • Peer Review Publications
  • Futile Hypothesis
  • NERD Receipt
  • InfoGraphics

NERD System Copyright © Federal Ministry of Education.

  • Cookie settings  | 
  • Terms and Conditions  |  
  • End Users Agreement  | 
  • Privacy Policy